Patrick Hawkins
Adult Health · Flint, MINPI 1902803877
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,598, 2.2 times the $733 reported in 2021. Among adult health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$723
- Lundbeck LLC$470
- E.r. Squibb & Sons, L.L.C.$356
- Otsuka America Pharmaceutical, Inc.$346
- Axsome Therapeutics, Inc.$302
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,65398%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $1,025 |
| Alkermes, Inc. | 42 | $723 |
| Lundbeck LLC | 27 | $470 |
| E.r. Squibb & Sons, L.L.C. | 12 | $356 |
| Otsuka America Pharmaceutical, Inc. | 6 | $346 |
| Axsome Therapeutics, Inc. | 7 | $302 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $289 |
| Akebia Therapeutics Inc | 13 | $242 |
| Neurocrine Biosciences, Inc. | 3 | $166 |
| Idorsia Pharmaceuticals US Inc | 1 | $115 |
| Vifor Pharma, Inc. | 5 | $112 |
| Braeburn Inc. | 1 | $81 |
| Amgen(2 entities) | 4 | $77 |
| Coloplast | 1 | $71 |
| Johnson & Johnson | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 1 | $45 |
| GSK | 2 | $33 |
| Fresenius USA Marketing, Inc. | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Novo Nordisk | 2 | $29 |
| AstraZeneca | 2 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Novartis | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,729 in reported general payments places this provider in the 90th percentile of 527 adult health providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 18 | $151,593 |
| Abilify AsimtufiiAripiprazole | 21 | $105,641 |
| Abilify MaintenaAripiprazole | 33 | $95,020 |
| RexultiBrexpiprazole | 51 | $75,841 |
| VraylarCariprazine Hcl | 44 | $63,249 |
| AuvelityDextromethorphan Hbr/Bupropion | 41 | $37,762 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $26,976 |
| CaplytaLumateperone Tosylate | 12 | $20,585 |
| TrintellixVortioxetine Hydrobromide | 17 | $12,157 |
| Aripiprazole | 40 | $8,962 |
| Lurasidone Hcl | 32 | $8,618 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,071 |
| Paliperidone ErPaliperidone | 15 | $5,322 |
| Oxtellar XrOxcarbazepine | 11 | $3,873 |
| Duloxetine Hcl | 122 | $2,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti | $346 | $276,502105 claims |
| Johnson & JohnsonInvega Trinza | $66 | $151,59318 claims |
| AbbVieVraylar | $1,025 | $63,24944 claims |
| Axsome Therapeutics, Inc.Auvelity | $302 | $37,76241 claims |
| Alkermes, Inc.Lybalvi | $723 | $26,97618 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $289 | $20,58512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 adult health providers in Michigan.
Other adult health in Flint
- Leslie ClasonFlint$4K
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.